Anti-Human Nerve Growth Factor (Tanezumab)

Humanized and affinity matured form of antibody clone E3. Immunogen unknown.

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Tanezumab. Tanezumab is a humanized antibody that specifically binds human and rodent nerve growth factor.

Nerve growth factor (NGF) is a neurotrophin that regulates the structure and function of responsive sensory neurons¹. In particular, NGF is involved in the transmission and sensation of inflammatory and neuropathic pain². NGF is elevated in patients with arthritis, pancreatitis, and prostatitis as well as in animal models of inflammatory pain³. Additionally, increased expression of NGF in injured or inflamed tissue is associated with increased pain while blocking NGF in animal models reduces signs of pain. Therefore, harnessing NGF for pain modulation via therapeutic antagonism is of interest for inflammatory disease management. An antibody-based analgesic would also potentially avoid the gastrointestinal and cardiorenal side effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and narcotics typically used for pain management and may also help avoid or delay surgical intervention.

Tanezumab is a humanized and affinity matured form of antibody clone E3⁴ that blocks the interaction between NGF and its receptors TrkA and p75¹. Tanezumab/NGF binding is extremely stable, with dissociation too slow to detect in both surface- and solution-based assays². Kinetics assays show that NGF binds as one whole homodimer to one tanezumab arm². An NGF dimer “half-saturated” with a single molecule of tanezumab can use its second subunit to bind either a second molecule of tanezumab or simultaneously bind TrkA or p75 in addition to tanezumab.

Tanezumab significantly reduces knee pain, stiffness, and limitations of physical function in patients with osteoarthritis³ and may have some therapeutic effect on lower back pain 1¹.

Nerve growth factor is produced by a number of cell types including mast cells, B lymphocytes, keratinocytes, smooth muscle cells, fibroblasts, bronchial epithelial cells, renal mesangial cells, and skeletal muscle myotubes. Nerve growth factor expression is increased in inflamed tissues.

Bind to receptors TrkA and p75

1 Webb MP, Helander EM, Menard BL, et al. Ther Clin Risk Manag. 14:361-367. 2018.
2 Abdiche YN, Malashock DS, Pons J. Protein Sci. 17(8):1326-1335. 2008.
3 Lane NE, Schnitzer TJ, Birbara CA, et al. N Engl J Med. 363(16):1521-1531. 2010.
4 United States Patent Application No. 20040237124; https://patents.google.com/patent/US20040237124A1/en